PRESS RELEASE
04 November 2026 13:00:00 CET

Lipum awarded Vinnova grant to increase knowledge of the biological effects of SOL-116

Lipum AB has been awarded SEK 992,000 by Vinnova for the project *Metabolomic fingerprints of SOL-116, from treatment to biological effect*. The project will use advanced metabolomics to increase knowledge of the biological effects of Lipum's drug candidate SOL-116 and to establish a foundation for continued biomarker development.

The project is being carried out in collaboration with the SciLifeLab's Drug Discovery and Development Platform and is based on analysis of collected plasma samples from Lipum's completed phase I clinical study of the drug candidate SOL-116. Using high-resolution mass spectrometry, the researchers will investigate whether treatment with SOL-116 gives rise to a specific metabolomic fingerprint.

The analysis covers both known metabolites and a broad, untargeted analysis of previously unknown metabolite markers. The aim is to identify metabolic changes, signaling pathways and potential biomarkers that can contribute to a deeper understanding of the pharmacological effects of SOL-116 and provide guidance for continued clinical development.

"This is an important step in our work to understand the biological effects of SOL-116 at a deeper level. By combining our unique clinical material with SciLifeLab's Drug Discovery and Development Platform, we can generate new knowledge that strengthens the continued development of SOL-116," says Ola Sandborgh, CEO of Lipum.

The project has been assessed as having very good potential to generate new knowledge and contribute to future biomarker development and clinical benefit. Vinnova also highlights the project team's expertise and access to suitable infrastructure as important prerequisites for high-quality implementation.

"By combining Lipum's plasma samples from the phase I study with SciLifeLab's Drug Discovery and Development Platform high-resolution mass spectrometry, we can both map known metabolites and search for entirely new biomarkers that show how SOL-116 affects the body. This is a clear example of how Swedish research infrastructure enables a life science company to generate data that would otherwise have been difficult to obtain. The results can provide valuable guidance for future decisions on how biomarkers can be used in the SOL-116 programme," says Kristian Sandberg, Co-Director, SciLifeLab's Drug Discovery and Development Platform.

The project runs from 1 November 2026 to 30 June 2027. The maximum grant from Vinnova is SEK 992,000 and is funded under the call *Utilising infrastructures for innovation in life science*.

PRESS RELEASE
04 November 2026 13:00:00 CET

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: **www.lipum.se**

About Us
Lipum AB based in Umeå, is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. Lipum's unique approach has attracted international attention and has been awarded EUR 8 million in EU funding for the Horizon Europe project BEYOND.

Attachments
Lipum awarded Vinnova grant to increase knowledge of the biological effects of SOL-116